Sermorelin

Sermorelin (GHRH 1–29) was the first GHRH analogue approved by the FDA, used clinically for diagnostic testing of GH secretion and treatment of idiopathic GH deficiency in children (Geref, Serono). It contains the first 29 amino acids of the 44-amino-acid endogenous GHRH sequence — the minimal active fragment sufficient for full GH-releasing activity at pituitary somatotrophs.

Unlike exogenous synthetic HGH, sermorelin preserves the natural pulsatile pattern of GH secretion, maintains hypothalamic-pituitary feedback regulation, and cannot cause acromegaly because it depends on functional pituitary somatotrophs. This regulatory constraint is considered a key safety advantage over direct HGH administration.

Off-label, sermorelin is widely used in age management medicine as an alternative to HGH for body composition optimization, improved sleep quality, and general anti-aging. It is typically administered at bedtime to coincide with the physiological GH pulse that accompanies deep sleep.

// GHRH RECEPTOR ACTIVATION

Sermorelin binds and activates GHRH receptors (GHRHR) on anterior pituitary somatotroph cells, triggering a cascade of intracellular cAMP signaling that promotes GH synthesis and release. The resulting GH pulse mirrors the natural physiological pattern — a critical distinction from flat-line exogenous HGH levels.

// PRESERVED SOMATOSTATIN FEEDBACK

Because sermorelin stimulates GH through the normal pituitary axis, somatostatin (SRIF) feedback is preserved. Elevated GH and IGF-1 trigger hypothalamic somatostatin release, which suppresses further GH secretion — preventing the supraphysiological IGF-1 elevations seen with HGH overdose.

// PITUITARY REGENERATIVE EFFECT

Chronic GHRH stimulation appears to maintain and potentially restore somatotroph cell populations. Age-related GH decline is partly mediated by reduced GHRH signaling rather than true pituitary failure — sermorelin addresses this upstream cause rather than simply replacing the downstream hormone.

FDA approval history: Sermorelin acetate (Geref, Serono) received FDA approval for GH stimulation testing and pediatric GH deficiency treatment. The commercial product was discontinued in the US in 2002 (Serono shifted focus to rhGH), but sermorelin remains available through compounding pharmacies and is widely used off-label.

Compared to CJC-1295 (no DAC) at equivalent doses, sermorelin has a shorter half-life (~10–20 min) and slightly lower receptor affinity, but its longer clinical track record and FDA history make it a favored choice in age management medicine. Often stacked with ipamorelin for synergistic GH release.